Enara Bio announces the appointment of T-cell therapy leader Dr. Sophie Papa as Chief Medical Officer Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist. Enara Bio’s presentation on development of an MR1-targeting T cell therapy from the 12th International CD1-MR1 EMBO Meeting Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director Enara Bio participates in Boehringer Ingelheim’s “Taking Cancer On” podcast series Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today. Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June. Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach. Enara Bio adds further world-class cell therapy and immuno-oncology expertise to Senior Management Team and Scientific Advisory Board Dr Erik Rutjens appointed as Vice President, Cell Therapy Operations Dr Sadik Kassim and Dr Michael Quigley strengthen Scientific Advisory Board with deep industry experience Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies Enara’s move from the Oxford BioEscalator to one of the UK's largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program.